189333-48-0

Usage

Uses

Used in Pharmaceutical Industry:
9-BENZYL-3,9-DIAZA-SPIRO[5.5]UNDECANE-2,4-DIONE is used as a potential pharmacophore for designing new drugs targeting various diseases. Its unique chemical structure allows it to exhibit various biological activities, making it a promising candidate for drug discovery and development.
Used in Organic Synthesis:
9-BENZYL-3,9-DIAZA-SPIRO[5.5]UNDECANE-2,4-DIONE serves as a building block for the creation of other complex chemical compounds. Its versatile structure makes it a valuable component in organic synthesis, contributing to the development of novel chemical entities with potential applications in various fields.
Used in Drug Discovery and Development:
9-BENZYL-3,9-DIAZA-SPIRO[5.5]UNDECANE-2,4-DIONE is used as a starting point for the development of new drugs. Its unique chemical properties and potential biological activities make it an attractive candidate for further research and exploration in the pharmaceutical industry.

InChI:InChI=1/C16H20N2O2/c19-14-10-16(11-15(20)17-14)6-8-18(9-7-16)12-13-4-2-1-3-5-13/h1-5H,6-12H2,(H,17,19,20)

Upstream product

• 769901-73-7 2,2'-(1-benzylpiperidine-4,4-diyl)diacetic acid 
• 1176981-06-8 1'-benzyl-3,7-diazaspiro[bicyclo[3.3.1]nonane-9,4'-piperidine]-2,4,6,8-tetraone 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 189333-46-8 9-benzyl-2,4-dioxo-3,9-diazaspiro[5,5]undecane-1,5-dicarbonitrile 

Downstream Products

• 189333-49-1 3-benzyl-3,9-diazaspiro[5.5]undecane 
• 1338706-96-9 C₃₃H₃₉ClN₂O₅ 
• 13323-40-5 3-benzyl-9-methyl-3,9-diaza-spiro[5.5]undecane 
• 1001054-49-4 3-benzyl-9-cyclobutyl-3,9-diazaspiro[5.5]undecane 

Relevant academic research and scientific papers

3,9- DIAZASPIRO[5,5] UNDECANE COMPOUND AS FLT3 AND AXL INHIBITORS

Disclosed in the present invention is a novel compound as FLT3 and AXL inhibitors. Sepcifically, disclosed are a compound represented by fomula (I) and a pharmacologically acceptable salt thereof.

Preparation method of 3-alkyl-3, 9-diazaspiro [5, 5] undecane

The invention relates to a preparation method of 3-alkyl-3, 9-diazaspiro [5, 5] undecane. The preparation method comprises the following steps: a. reacting a compound I with cyanoacetate under the action of ammonia water and a catalyst to obtain a compoun

Polymorphism of novel spiroarylphosphine oxide

The invention relates to a polymorphic substance of a compound (2-((5-chloro-2-((2-methoxyl-4-(9-methyl-3,9-diaza-sprio[5.5]hendecane-3-yl)phenyl)amino)pyrimidine-4-yl)amino)phenyl)dimethyl phosphineoxide (compound I). The invention further relates to a m

Preparation method, intermediate and crystal form of spironolamine arylphosphine oxide

The invention discloses a preparation method and a crystal form of high-purity spironolamine arylphosphine oxide. The invention further discloses a method for preparing a compound shown as a formula (I) and an intermediate compound.

Spiro aryl phosphorus oxide or sulfide

The invention discloses a spiro aryl phosphorus oxide or sulfide as ALK inhibitor, and in particular discloses a compound shown in a formula (I) as an ALK inhibitor or a pharmaceutically acceptable salt thereof.

CEPHEM COMPOUND HAVING CATECHOL GROUP

A compound of the formula: wherein X is -N=, -CH=, or the like; W is -CH2- or the like; U is -S- or the like; R1 and R2 are each independently hydrogen, halogen, optionally substituted lower alkyl, or the like; R3/su

SUBSTITUTED AZASPIRO DERIVATIVES

Substituted azaspiro derivatives of the Formula:are provided, in which variables are as described herein. Such compounds may be used to modulate ligand binding to histamine H3 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) and other disorders in humans, domesticated companion animals and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting histamine H3 receptors (e.g., receptor localization studies).

SPIROCYCLIC SULFONAMIDES AND RELATED COMPOUNDS

Spirocyclic sulfonamides and related compounds of Formula 1 are provided : (Formula (I)): in which the variables are as described herein. Such compounds may be used to modulate bradykinin receptor activity in vivo or in vitro, and are particularly useful

CGRP RECEPTOR ANTAGONISTS

Compounds of Formula (I): and Formula (II): (where variables R2, R4, A, B, D, W, X, Y and Z are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation

This invention relates to certain spirocyclic compounds substituted with both basic and acidic functionality, as shown by formula (I): wherein Q, L, Ai, Bj, R0, R3, R10, m, n, p and q are as defined in the disclosure, which are useful in inhibiting of platelet aggregation.